{"id":79667,"date":"2026-07-20T18:08:11","date_gmt":"2026-07-20T12:38:11","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=79667"},"modified":"2026-07-20T18:09:11","modified_gmt":"2026-07-20T12:39:11","slug":"india-non-animal-testing","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/current-affairs\/20-07-2026\/india-non-animal-testing","title":{"rendered":"India\u2019s Opportunity to Lead the Shift to Non-Animal Drug Testing"},"content":{"rendered":"\n<p><strong>Syllabus: GS3\/ Biotechnology, GS4\/ Ethics<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Non-Animal Testing Models (NAMs) are emerging as scientifically credible alternatives and complements to the traditional animal testing, presenting an opportunity for India to further strengthen its pharmaceutical innovation ecosystem.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What are Non-Animal Testing Models (NAMs)?&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-animal testing methods (NAMs)<\/strong> are scientific approaches that use human-relevant biological systems and computational methods to generate safety, efficacy and toxicity information, instead of relying solely on animal testing.<\/li>\n\n\n\n<li><strong>Types of NAM platforms are as;<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Organoids:<\/strong> Miniature three-dimensional structures grown from human stem cells that mimic the architecture and function of human organs.<\/li>\n\n\n\n<li><strong>Organ-on-chip systems:<\/strong> Microfluidic devices that recreate the physiological environment of human tissues and organ interactions.<\/li>\n\n\n\n<li><strong>Three-dimensional human cell culture models: <\/strong>Advanced cellular systems that better replicate human tissue behaviour than conventional two-dimensional cultures.<\/li>\n\n\n\n<li><strong>Computational toxicology: <\/strong>Computer-based models that predict chemical toxicity and drug responses using biological and chemical data.<\/li>\n\n\n\n<li><strong>Artificial Intelligence (AI)-enabled models:<\/strong> Machine learning systems that analyse large biomedical datasets to predict human drug responses.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why is a Shift Needed?<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Limitations of conventional animal testing:<\/strong> Animal physiology, metabolism, immune responses and disease mechanisms differ from those of humans, so traditional animal models often do not accurately predict human biological responses.<\/li>\n\n\n\n<li><strong>Drug development challenge:<\/strong> Globally, only about<strong> 10\u201314% <\/strong>of drug candidates entering Phase I clinical trials ultimately receive regulatory approval.\n<ul class=\"wp-block-list\">\n<li>A major reason is the inability of some preclinical models to reliably predict human safety and efficacy outcomes.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Ethical Considerations: <\/strong>These models reduce or eliminate the need for live animals (such as rodents and primates) in painful or fatal testing procedures.<\/li>\n\n\n\n<li><strong>India\u2019s Existing Strengths: <\/strong>India possesses a robust generic pharmaceutical industry, enabling it to emerge as a major global supplier of affordable medicines.\n<ul class=\"wp-block-list\">\n<li>However, future growth in the pharmaceutical sector will increasingly depend on innovation-driven value creation rather than only large-scale manufacturing.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Global Trends in NAM Adoption<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The United States<\/strong> has passed the <strong>FDA Modernization Act 2.0<\/strong> officially ending the decades-old federal mandate that required animal testing for all new drug applications.<\/li>\n\n\n\n<li><strong>The European Union<\/strong>: The EU has a deeply integrated approach to safety testing under the<strong> REACH framework<\/strong>.\n<ul class=\"wp-block-list\">\n<li><strong>The European Commission and the European Chemicals Agency (ECHA) <\/strong>adopted a comprehensive roadmap to completely phase out animal testing for chemical safety assessments.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>The United Kingdom<\/strong> has created national centres and research networks focused on human-relevant testing technologies and<strong> the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)<\/strong> is the primary organization leading this.<\/li>\n\n\n\n<li><strong>Japan: <\/strong>Japan has invested in toxicology infrastructure through the <strong>Japanese Center for the Validation of Alternative Methods (JaCVAM)<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Evolution of NAM Use in India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>The Department of Biotechnology<\/strong> has undertaken initiatives to nurture and develop 3D tissue models like <strong>organoid models or in-vitro systems- 3D printed models<\/strong> for potential applications in <strong>cell therapy, pre-clinical models for drug discovery, in-vitro cell based models<\/strong> for understanding disease pathophysiology.<\/li>\n\n\n\n<li>Platforms such as<strong> Caenorhabditis elegans (C. elegans), Drosophila melanogaster, zebrafish systems, and yeast-based models<\/strong> have been adopted for toxicology, disease modelling and drug screening.<\/li>\n\n\n\n<li>India recognised Non-Animal Testing Models (NAMs) in the drug-development pipeline by amending the <strong>New Drugs and Clinical Trials Rules, 2019 in 2023.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Opportunities for India<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strengthen intellectual property creation: <\/strong>Advanced testing platforms support original drug discovery, novel biologics and proprietary technologies, thereby helping India generate stronger patents and innovation-based intellectual property.<\/li>\n\n\n\n<li><strong>India\u2019s global competitiveness:<\/strong> Early adoption of human-relevant testing technologies can attract international collaborations, investment and high-value research projects, positioning India as a global hub for drug discovery and biomedical innovation.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Way Ahead<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India should <strong>integrate NAMs into generic drug quality assessment and biosimilar development <\/strong>through a phased approach that does not disrupt existing manufacturing systems.<\/li>\n\n\n\n<li>India should <strong>establish a national regulatory framework for NAMs,<\/strong> with clear validation protocols, data acceptance guidelines and coordination among regulatory agencies, industry and research institutions.<\/li>\n\n\n\n<li>Early adoption of NAMs will <strong>position India as a preferred destination <\/strong>for innovative drug discovery, translational research and next-generation pharmaceutical development.<\/li>\n<\/ul>\n\n\n\n<p><strong>Source: <\/strong><a href=\"https:\/\/www.thehindu.com\/sci-tech\/health\/indias-opportunity-to-lead-the-shift-to-non-animal-drug-testing\/article71206055.ece\" target=\"_blank\" rel=\"noopener\"><strong>TH<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong> Context <\/strong><\/p>\n<li class=\"ms-5\"> The Non-Animal Testing Models (NAMs) are emerging as scientifically credible alternatives and complements to the traditional animal testing, presenting an opportunity for India to further strengthen its pharmaceutical innovation ecosystem. <\/li>\n<p><\/p>\n<p><strong> What are Non-Animal Testing Models (NAMs)?\u00a0 <\/strong><\/p>\n<li class=\"ms-5\"> Non-animal testing methods (NAMs) are scientific approaches that use human-relevant biological systems and computational methods to generate safety, efficacy and toxicity information, instead of relying solely on animal testing. <\/li>\n<li class=\"ms-5\"> Types of NAM platforms are as; <\/li>\n<li class=\"ms-5\"> Organoids: Miniature three-dimensional structures grown from human stem cells that mimic the architecture and function of human organs. <\/li>\n<p><a href=\" https:\/\/www.nextias.com\/ca\/current-affairs\/20-07-2026\/india-non-animal-testing \" class=\"btn btn-primary btn-sm float-end\">Read More<\/a><\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-79667","post","type-post","status-publish","format-standard","hentry","category-current-affairs"],"acf":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/79667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=79667"}],"version-history":[{"count":2,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/79667\/revisions"}],"predecessor-version":[{"id":79670,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/79667\/revisions\/79670"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=79667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=79667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=79667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}